SB 205952
Latest Information Update: 17 Nov 1999
At a glance
- Originator GlaxoSmithKline
- Class Antibacterials
- Mechanism of Action Isoleucyl tRNA synthetase inhibitors; RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 17 Nov 1999 Discontinued-Preclinical for Bacterial infections in United Kingdom (Unknown route)
- 04 Aug 1998 No-Development-Reported for Bacterial infections in United Kingdom (Unknown route)
- 26 Oct 1995 New profile